2. Biomarkers Defnitions Working Group. Biomarkers and surrogate endpoints: preferred defnitions and conceptual framework. Clin Pharmacol Ther. 2001; 69:89–95.
3. International Programme on Chemical Safety. Biomarkers in risk assessment: validity and validation. World Health Organization, Geneva, 2001.
4. Sölétormos G, Duffy MJ, Hassan SOA, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). Int J Gynecol Cancer. 2016; 26:43-51.
5. Muinao T, Deka Boruah HP, Pal M. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review. Exp Cell Res. 2018; 362:1-10.
6. Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017; 17:577-591.
7. Guo N, Peng Z. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study. J Ovarian Res. 2017; 10:14.
8. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343:692–695.
9. National Cancer Institute Dictionary of Cancer Terms https ://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed 7 Sept., 2020.
10. Chiyoda T, Dozen A, Saotome K, Nanki Y, Aoki D. In: Shimada H (eds), Biomarkers of gynecological cancers. Biomarkers in Cancer Therapy: Liquid Biopsy Comes of Age. 2019. Pp. 133-150.
11. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterol. 1999; 116:1453–1456.
12. Mathews J, Amaravadi L, Eck S, Stevenson L, Wang YM, Devanarayan V, et al. Best practices for the development and ftfor-purpose validation of biomarker methods: a conference report. AAPS Open. 2022; 8:2.
13. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum. 1991; 34:424–425.
14. Edwards P, Monahan KJ. Diagnosis and management of Lynch syndrome. Frontline Gastroenterol. 2022; 13(e1):e80-e87.
15. Clark SK. Management of genetically determined colorectal cancer. Surgeon. 2019; 17(3):165–171.
16. Mai PL, Malkin D, Garber JE, et al. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012; 205:479–487
17. Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol Suppl. 2021; 116(3):458–479.
18. Sanchez-Mete L, Stigliano V. Update on small bowel surveillance in hereditary colorectal cancer syndromes. Tumori. 2019; 105(1):12–21.
19. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003; 21:313–313
20. Ji M, Wang L, Shao Y. A novel dysfunctional germline P53 mutation identified in a family with Li-Fraumeni syndrome. Am J Cancer Res. 2018; 8:165–169.
21. Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni syndrome. In: Adam M, Ardinger H, Pagon R, et al., eds. GeneReviews. www.ncbi.nlm.nih. gov/books/. Published January 19, 1999. Updated April 11, 2013. Accessed January 1, 2020.
22. Ponikowski P, Voors AA, Anker SD et al ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016; 18:891–975.
23. Biomarkers Defnitions Working Group. Biomarkers and surrogate endpoints: preferred defnitions and conceptual framework. Clin Pharmacol Ther. 2001; 69:89–95.
24. Zamwar UM, Anjankar AP. Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. Cureus. 2022; 14:e30561.
25. Shastri SS, Temin S, Almonte M, Basu P, Campos NG, Gravitt PE, et al. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update. JCO Global Oncol. 2022; 8:e2200217.
26. Monti M, D’Aniello D, Scopelliti A, Tibaldi V, Santangelo G, Colagiovanni V, et al. Relationship between cervical excisional treatment for cervical intraepithelial neoplasia and obstetrical outcome. Minerva Obstetrics and Gynecology. 2021; 73:233-246.
27. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. The New Engl J Med. 2022; 386:437–448.
28. Zamwar UM, Anjankar AP. Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. Cureus. 2022; 14:e30561.
29. Kim SI, Kim JW. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO Open. 2021; 6:100149.
30. Verbakel JY, Heremans R, Wynants L, Epstein E, De Cock B, Pascual MA, et al. Risk assessment for endometrial cancer in women with abnormal vaginal bleeding: Results from the prospective IETA-1 cohort study. Int J Gynaecol Obstet. 2022; 159: 103–110.
31. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019; 12:28.
32. Kim BG. Squamous cell carcinoma antigen in cervical cancer and beyond. J Gynecol Oncol. 2013; 24(4):291.
33. Güzel C, van Sten-Van’t Hoff J, de Kok IMCM, et al. Molecular markers for cervical cancer screening. Exp Rev Proteomics. 2021; 18(8):675-691.
34. Miao M, Miao Y, Zhu Y, Wang J, Zhou H. "Advances in Exosomes as Diagnostic and Therapeutic Biomarkers for Gynaecological Malignancies." Cancers. 2022; 14(19):4743.
35. Carser JE, Quinn JE, Michie CO, O’Brien EJ, McCluggage WG, Maxwell P, Lamers E, Lioe TF, Williams AR, Kennedy RD, Gourley C, Harkin DP. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol. 2011; 123(3):492-498.
36. Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011; 12(2):165-173.
37. Robinson WH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol. 2013; 9(5):267-276.
38. Seo Y, Park YH, Ahn JS, et al. PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. J Breast Cancer. 2018; 21(4):382-390.
39. Yang J, Nie J, Ma X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18:26.
40. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Int Med. 1996; 125(7):605-13.
41. Nimse SB, Sonawane MD, Song KS, Kim T. Biomarker detection technologies and future directions. Analyst. 2016; 141(3):740-755.
42. Brenner DE, Normolle DP. Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):1918-1920.
43. Ahmed RM, Paterson RW, Warren JD, Zetterberg H, O'brien JT, Fox NC, Halliday GM, Schott JM. Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry. 2014; 85(12):1426-1434.
44. Lim C, Tsao MS, Le LW, Shepherd FA, Feld R, Burkes RL, Liu G, Kamel-Reid S, Hwang D, Tanguay J, da Cunha Santos G. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol. 2015; 1;26(7):1415-21.
45. Zhu W, Lévy-Leduc C, Ternès N. Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso. BMC Bioinformatics. 2023; 23; 24(1):25.
46. De Lorenzo SB, Patel AG, Hurley RM, et al. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol. 2013; 3:228.
47. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434:917-921.
48. Ledermann J, Harter P, Gourley C. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014; 15:852-861.
49. Armstrong DK, Alvarez RD, Bakkum-Gamez JN. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:191-226.
50. Shah S, Cheung A, Kutka M. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. Int J Environ Res Pub Health. 2022; 19:8113.
51. Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K. NCCN Guidelines® insights: Ovarian cancer, version 3.2022. J Natl Compr Canc Netw. 2022; 20(9):972–980.
52. Miller RE, Leary A, Scott CL, Lord CJ, Bowtell D, Chang DK. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020; 31(12):1606–1622.
53. Li H, Liu ZY, Wu N., Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: The underlying mechanisms and clinical implications. Mol Cancer. 2020; 19(1):107.
54. Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian cancer: Adjuvant, combination, and neoadjuvant. Front. Immunol. 2020; 11:577869.
55. Antoniou M, Kolamunnage-Dona R, Wason J, Bathia R, Billingham C, Bliss JM, Brown LC, Gillman A, Paul J, Jorgensen AL. Biomarker-guided trials: challenges in practice. Contemp Clin Trials Commun. 2019; 16:100493.
56. Schuhn A, Tobar TW, Gahlawat AW, Hauke J, Baumann L, Okun JG, Nees J. Potential of blood-based biomarker approaches in endometrium and breast cancer: a case-control comparison study. Arch Gynecol Obstet. 2022; 306(5):1623-1632.
57. Zannoni GF, Bragantini E, Castiglione F, Fassan M, Troncone G, Inzani F, Pesci A, Santoro A, Fraggetta F. Current prognostic and predictive biomarkers for endometrial cancer in clinical practice: Recommendations/proposal from the Italian study group. Front Oncol. 2022; 12:805613.
58. Chiyoda T, Dozen A, Saotome K, Nanki Y, Aoki D. Biomarkers of gynecological cancers. Biomarkers in Cancer Therapy: Liquid Biopsy Comes of Age. 2019:133-150.
59. Mathews J, Amaravadi L, Eck S, Stevenson L, Wang YM, Devanarayan V, Allinson J, Lundsten K, Gunsior M, Ni YG, Pepin MO. Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report. AAPS Open. 2022; 8(1):2.
60. Wang YC, Strauss DG, Huang SM. Use of pharmacodynamic/response biomarkers for therapeutic biologics regulatory submissions. Biomark Med. 2019; 13(10):805–809.
61. Clark TJ, Middleton LJ, Cooper NA. A randomised controlled trial of laparoscopic uterosacral nerve ablation for women with chronic pelvic pain. BMJ Open. 2015; 5:e006408.
62. Sarlos D, Kots L, Stevanovic N, Schaer G. Robotic compared with conventional laparoscopic hysterectomy: a randomized controlled trial. Obstet Gynecol. 2012; 120:604-611.
63. Payne TN, Dauterive FR. A comparison of total laparoscopic hysterectomy to robotically assisted hysterectomy: surgical outcomes in a community practice. J Minim Invasive Gynecol. 2008; 15:286-291.
64. Holloway RW, Patel SD, Ahmad S, Robichaux AG, Goravanchi F, et al. Robotically assisted gynecologic surgery in the obese patient. Am J Obstet Gynecol. 2009; 200:613.e1-613.e4.
65. Moore RG, Miller MC, Eklund EE. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012; 206:349.e1-349.e7.
66. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet. 1978; 2:366.
67. Aungst TD. Medical applications for pharmacists using mobile devices. Ann Pharmacother. 2013; 47:1088-1095.
68. Freis A, Freundl-Schütt T, Wallwiener LM, Wallwiener CW, Wallwiener D. Bioinformatics support for the fertility awareness-based methods in avoiding pregnancy. Reprod Biomed Online. 2017; 35:308-316.
69. Ong MS, Magrabi F, Post J, Morris S, Westbrook JI. Use of clinical decision support to improve primary care identifies targets for improvement in the outpatient referral process. J Am Med Inform Assoc. 2016; 23:609-615.
70. Silverstein W, Lass E, Bornstein T. A randomized clinical trial of a telemedicine intervention for child disruptive behavior disorders: III. Maintenance and generalization of effects. J Abnorm Child Psychol. 2018; 46:1285-1298.
71. Wac K, Wac K, Prakoonwit S, Widya I, Jara AJ. Mobile healthcare and resource-constrained communities: a case study from Thailand. J Med Syst. 2012; 36:1437-1451.
72. Henselmans I, van Laarhoven HW, van der Vloodt J, Tokat M, Engelhardt EG. Shared decision making about palliative chemotherapy: A qualitative observation of talk about patients’ preferences. Palliat Med. 2015; 29:261-269.
- Abstract viewed - 214 times
- PDF downloaded - 75 times
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright
© ES Omozuwa, K Atoe, 2024
Affiliations
ES Omozuwa
Department of Obstetrics and Gynaecology, Edo State University Uzairue, Edo State, Nigeria
K Atoe
Department of Chemical Pathology, Edo State University Uzairue, Edo State, Nigeria
How to Cite
Evaluating the Efficacy of Biomarkers in the Diagnosis and Treatment of Gyneacological Malignancies: A Review
Vol 10 No 2 (2024): Volume 10 Number 2
Submitted: Sep 27, 2024
Published: Sep 27, 2024
Abstract
The current review examines the pivotal role of biomarkers in the diagnosis and treatment of gynaecological cancers, with emphasis on ovarian cancer. It explores how biomarkers such as CA125 and HE4 are used to predict disease onset, detect subclinical illness, and assess treatment responses, especially in the context of ovarian cancer recurrence. The review also addresses the challenges inherent in early detection and management of gynaecological cancers, highlighting the asymptomatic nature and high mortality rate associated with ovarian cancer. It underscores the potential of biomarkers to significantly enhance early detection and treatment strategies, thereby improving patient outcomes. Additionally, this review discusses the relevance of biomarkers across various gynaecological cancers, including cervical, endometrial, and vulvar malignancies, outlining associated risk factors and treatment options. Finally, the review emphasizes the need for further research to validate and integrate effective biomarkers into clinical practice, with the aim of advancing the management of gynaecological cancers